Gastric Cancer
Conditions
Keywords
propranolol, gastric cancer
Brief summary
At the cellular and animal level, we found that propranolol can inhibit the proliferation and invasion of gastric cancer cells. Further, we want to explore the efficacy and safety of propranolol in the treatment of gastric cancer patients.
Interventions
DRUGPropranolol
add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
Sponsors
Xiangya Hospital of Central South University
Yijing He
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must provide written informed consent. 2. age 18 to 75;Confirmed as a primary gastric adenocarcinoma patient by imaging and histology or cytology; 3. Patients with advanced gastrointestinal cancer who have received no prior chemotherapy or radiotherapy for malignant tumors; 4. Patients with Eastern Cooperative Oncology Group Performance Status of 0 or 1. 5. Patients with a life expectancy of at least three months.; 6. Organ function and hematopoietic function must meet the following requirements: hemoglobin (HGB) ≥ 90g / L; white blood cell count (WBC) ≥ 3 × 10 \^ 9 / L; absolute neutrophil count (ANC) ≥ 1.5 × 10 \^ 9 / L Platelet count (PLT) ≥ 100 × 10 \^ 9 / L; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase ( ALT)≤2.5×ULN; if abnormal liver function is due to tumor liver metastasis, AST or ALT≤5×ULN; serum creatinine (Cr)≤1.5×ULN; international normalized ratio (INR) or plasma prothrombin time ( PT) ≤ 1.5 × ULN. 7. Systolic blood pressure 90-140mmHg, diastolic blood pressure 60-90mmHg, heart rate 60-100bpm. 8. No previous cardiovascular and cerebrovascular diseases, and exclusion of atrioventricular block by 24-hour ambulatory electrocardiography; 9. subjects must agree to take effective contraceptive measures between the subject and the partner after signing the informed consent, during the study period and within 5 months after the last dose.
Exclusion criteria
1. There are clinical symptoms or diseases of the heart that are not well controlled, such as uncontrolled high blood pressure, unstable angina, or myocardial infarction within 6 months prior to enrollment, or poorly controlled arrhythmias (including QTc ( men ≥ 450ms , female ≥ 470ms, QTc interval calculated by Fridericia formula), cardiogenic shock, heart block (II-III degree atrioventricular block), severe or acute heart failure, sinus bradycardia, need continuous oxygen Treated severe respiratory diseases; 2. Subjects with symptomatic autoimmune diseases \[such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, decreased thyroid function; The tester has vitiligo or has completely relieved asthma in childhood, and can be included without any intervention after adulthood; asthma that requires bronchodilators for medical intervention cannot be included\] 3. Patients with other malignant tumors within 5 years prior to enrollment, in addition to appropriate treatment of cervical carcinoma in situ, cured skin basal cell carcinoma; 4. Immunodeficiency, such as a patient with HIV infection or other acquired, congenital immunodeficiency disease, or a history of organ transplantation 5. Patients with active tuberculosis infection by medical history or CT examination, or a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year without formal treatment; 6. Patients with tumor brain metastasis and bone marrow metastasis 7. Patients who participated in other drug clinical studies within 4 weeks; 8. Patients with history of hypersensitivity to any drugs in this study; 9. Identified as neurological or psychiatric disorders, such as epilepsy, dementia, poor compliance; 10. Alcohol abuse, drug abuse in the past year; 11. Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA (HBV DNA) \> 10 \^ 3 copies / mL, or hepatitis C virus antibody positive; syphilis positive; 12. Subjects had active infection or unexplained fever \>38.5 degrees during Screening period before the first dose (according to the researcher, the subject can be enrolled due to fever generated by the tumor.); 13. Clinical symptoms of ascites or pleural effusion, requiring therapeutic puncture or drainage; 14. Female patients who are pregnant or lactating, or planning to become pregnant or lactating; 15. Other patients who are considered to be unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Preoperative assessment | CR+PR |
Countries
China
Outcome results
None listed